Los Angeles Capital Management LLC Has $658,000 Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Los Angeles Capital Management LLC cut its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 11.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 86,533 shares of the biotechnology company’s stock after selling 11,044 shares during the quarter. Los Angeles Capital Management LLC’s holdings in BioCryst Pharmaceuticals were worth $658,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in BCRX. ProShare Advisors LLC grew its position in shares of BioCryst Pharmaceuticals by 9.1% in the 1st quarter. ProShare Advisors LLC now owns 48,503 shares of the biotechnology company’s stock valued at $246,000 after acquiring an additional 4,041 shares during the period. XTX Topco Ltd grew its holdings in BioCryst Pharmaceuticals by 299.0% during the second quarter. XTX Topco Ltd now owns 156,946 shares of the biotechnology company’s stock worth $970,000 after purchasing an additional 117,607 shares during the period. Seven Eight Capital LP increased its position in BioCryst Pharmaceuticals by 1,407.1% during the second quarter. Seven Eight Capital LP now owns 169,612 shares of the biotechnology company’s stock worth $1,048,000 after buying an additional 158,358 shares during the last quarter. Rice Hall James & Associates LLC raised its stake in BioCryst Pharmaceuticals by 4.0% in the third quarter. Rice Hall James & Associates LLC now owns 2,163,743 shares of the biotechnology company’s stock valued at $16,444,000 after buying an additional 84,102 shares during the period. Finally, Semanteon Capital Management LP acquired a new stake in shares of BioCryst Pharmaceuticals in the third quarter valued at approximately $1,137,000. 85.88% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. Needham & Company LLC restated a “buy” rating and issued a $14.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. Royal Bank of Canada restated an “outperform” rating and set a $10.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. Barclays upped their price target on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 5th. HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, August 6th. Finally, StockNews.com upgraded BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, August 6th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, BioCryst Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $14.67.

BioCryst Pharmaceuticals Trading Down 5.6 %

NASDAQ BCRX opened at $7.03 on Friday. The company has a market cap of $1.46 billion, a price-to-earnings ratio of -11.52 and a beta of 1.89. BioCryst Pharmaceuticals, Inc. has a 1-year low of $4.03 and a 1-year high of $8.88. The company has a 50 day moving average of $7.70 and a 200-day moving average of $7.14.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.07). The company had revenue of $117.10 million for the quarter, compared to analyst estimates of $113.99 million. During the same period last year, the company posted ($0.19) earnings per share. The business’s revenue for the quarter was up 35.1% compared to the same quarter last year. On average, equities research analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.38 earnings per share for the current year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.